United States - English - NLM (National Library of Medicine)

azurity pharmaceuticals, inc. - triptorelin (unii: 9081y98w2v) (triptorelin - unii:9081y98w2v) - triptorelin 22.5 mg in 2 ml - triptodur is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (cpp). - hypersensitivity: triptodur is contraindicated in individuals with a known hypersensitivity to triptorelin, any other component of the product, or other gnrh agonists or gnrh [see adverse reactions (6.2)] . - pregnancy: triptodur may cause fetal harm [see use in specific populations (8.1)] . risk summary triptodur is contraindicated in women who are pregnant [see contraindications (4)] since expected hormonal changes that occur with triptodur treatment increase the risk for pregnancy loss. available data with triptorelin use in pregnant women are insufficient to determine a drug-associated risk of adverse developmental outcomes. based on mechanism of action in humans and findings of increased pregnancy loss in animal studies, triptodur may cause fetal harm when administered to pregnant women. advise pregnant women of the potential risk to a fetus. the estimated background risk of m

United States - English - NLM (National Library of Medicine)

allergan, inc. - triptorelin pamoate (unii: 08an7wa2g0) (triptorelin - unii:9081y98w2v) - triptorelin 3.75 mg in 2 ml - trelstar is indicated for the palliative treatment of advanced prostate cancer [see  clinical studies (14) ]. trelstar is contraindicated in individuals with a known hypersensitivity to triptorelin or any other component of the product, or other gnrh agonists or gnrh [see warnings and precautions (5.1) ]. risk summary based on findings in animal studies and mechanism of action, trelstar can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1) ] . expected hormonal changes that occur with trelstar treatment increase the risk for pregnancy loss. in animal developmental and reproductive toxicology studies, daily administration of triptorelin to pregnant rats during the period of organogenesis caused maternal toxicity and embryo-fetal toxicities, including loss of pregnancy, at doses as low as 0.2, 0.8, and 8 times the estimated human daily dose based on body surface area. advise pregnant patients and females of reproductive potential of the potential risk to the fetus. dat

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - triptorelin acetate - solution for injection - triptorelin acetate 0.1 mg/ml - triptorelin - triptorelin - ivf

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - powder and solvent for suspension for injection - triptorelin as embonate 11.25 mg - triptorelin - triptorelin - - lowering of sexual hormones and- treatment of advanced hormone-dependent prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - triptorelin acetate, quantity: 100 microgram (equivalent: triptorelin, qty 95.6 microgram/ml) - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium chloride - decapeptyl 100 micrograms/1 ml is indicated for down-regulation and prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (art).,in clinical trials decapeptyl 100 micrograms/1 ml has been used in cycles where urinary and recombinant human follicle stimulating hormone (fsh) as well as human menopausal gonadotrophin (hmg) were used for stimulation.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 31 mg (equivalent: triptorelin, qty 22.5 mg) - suspension, powder for - excipient ingredients: polyglactin; carmellose sodium; polysorbate 80; mannitol - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.,diphereline 22.5mg 6 month formulation only:,diphereline 22.5 mg is indicated for the treatment of children 2 years and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 19.32 mg - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 5.6 mg (equivalent: triptorelin, qty 3.75 mg) - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vetoquinol australia pty ltd - triptorelin acetate - unknown - triptorelin acetate anthelmintic active 0.0 - active constituent

New Zealand - English - Ministry for Primary Industries

vetoquinol new zealand limited - triptorelin acetate - triptorelin acetate 0.01 g/litre - endocrine agent (hormone)